The EMRA offices will be closed for the upcoming holidays from Tuesday, December 24, 2024 thru Wednesday, January 1, 2025. We apologize for the inconvenience.
In this underpowered RCT, no evidence was found that TXA limits HE nor that it improves clinical outcomes by 90 days in NOAC-associated ICH. That being said, there were no major safety concerns noted
The PATCH-Trauma Trial confirms short-term benefits of tranexamic acid (TXA) for prehospital treatment of the bleeding trauma patient, despite no evidence of long-term functional benefits.